Pharsight

Prezcobix generic

Prezcobix is an antiviral drug owned by Janssen Prods. It contains two active ingredients, Cobicistat and Darunavir, and was first authorized for market use on January 29, 2015. In total, Prezcobix holds 6 drug patents, all of which are currently still effective.

When will Prezcobix generic be available?

The last patent of Prezcobix is set to expire on October 6, 2032, entitled 'Use of solid carrier particles to improve the processability of a pharmaceutical agent'. As such, the generics of Prezcobix are expected to be released after this date.

Prezcobix uses

Prezcobix is used for the treatment of HIV infection. The function of its active ingredients provides a two-pronged approach in combating the virus. Cobicistat acts as a pharmacokinetic enhancer that inhibits cytochrome P450 monooxygenase, which helps increase the effectiveness of other antiviral drugs. Darunavir, on the other hand, is an HIV protease inhibitor that prevents the virus from multiplying in the body. This drug can be administered to adults and paediatric patients weighing at least 40kg.

Prezcobix patent expiration

Prezcobix has a total of 6 patents, the last of which expires on Oct 6, 2032. The patents cover a range of discoveries, from the pseudopolymorphic forms of HIV protease inhibitor to the use of solid carrier particles in improving a drug's processability. The availability of Prezcobix generic is anticipated after this date. Below are the details of the patent:

EPO Oppostions filed on Prezcobix

Litigations filed on Prezcobix

Prezcobix dosage

Want to ask something?